Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.3151
-0.0515 (-14.05%)
At close: Jun 27, 2025, 4:00 PM
0.3059
-0.0092 (-2.92%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.06M in the quarter ending March 31, 2025, a decrease of -36.85%. This brings the company's revenue in the last twelve months to $5.21M, down -14.43% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.21M
Revenue Growth
-14.43%
P/S Ratio
0.56
Revenue / Employee
$247,905
Employees
21
Market Cap
16.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PSTV News
- 1 day ago - Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary - GlobeNewsWire
- 2 days ago - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET - GlobeNewsWire
- 2 days ago - Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer - GlobeNewsWire
- 3 days ago - Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - GlobeNewsWire
- 7 weeks ago - Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewsWire